$1.35+0.07 (+5.47%)
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease.
Pulmonx Corporation in the Healthcare sector is trading at $1.35. The stock is currently near its 52-week low of $1.13, remaining 23.7% below its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why LUNG maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pul...
Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.
Moby summary of Pulmonx Corporation's Q1 2026 earnings call
Pulmonx Corp (LUNG) demonstrates resilience with operational momentum and strategic expansion despite revenue challenges.
Pulmonx (NASDAQ:LUNG) reported first-quarter 2026 worldwide revenue of $20.6 million, as management emphasized early progress on commercial execution, continued advancement of its AeriSeal clinical program, and actions to reduce spending and extend its cash runway. Executives reiterated full-year 20
Pulmonx (LUNG) delivered earnings and revenue surprises of 0.00% and +2.52%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?